Warning: The NCBI web site requires JavaScript to function. more...
Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts.
Kasukabe T, Okabe-Kado J, Kato N, Sassa T, Honma Y.
Breast Cancer Res. 2005;7(6):R1097-110. Epub 2005 Nov 9.
Related citations
Cotylenin A, a new differentiation inducer, and rapamycin cooperatively inhibit growth of cancer cells through induction of cyclin G2.
Kasukabe T, Okabe-Kado J, Honma Y.
Cancer Sci. 2008 Aug;99(8):1693-8.
Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M.
Clin Cancer Res. 2004 Dec 1;10(23):8059-67.
Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis.
Lewis-Wambi JS, Kim HR, Wambi C, Patel R, Pyle JR, Klein-Szanto AJ, Jordan VC.
Breast Cancer Res. 2008;10(6):R104. Epub 2008 Dec 5.
Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells.
Le XF, Arachchige-Don AS, Mao W, Horne MC, Bast RC Jr.
Mol Cancer Ther. 2007 Nov;6(11):2843-57.
Combined antitumor activity of 7-hydroxystaurosporine (UCN-01) and tamoxifen against human breast carcinoma in vitro and in vivo.
Koh J, Kubota T, Koyama T, Migita T, Hashimoto M, Hosoda Y, Kitajima M.
Breast Cancer. 2003;10(3):260-7.
Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth.
Patel JB, Mehta J, Belosay A, Sabnis G, Khandelwal A, Brodie AM, Soprano DR, Njar VC.
Br J Cancer. 2007 Apr 23;96(8):1204-15. Epub 2007 Mar 27.
Antitumor effect of cotylenin A plus interferon-alpha: possible therapeutic agents against ovary carcinoma.
Honma Y, Kasukabe T, Yamori T, Kato N, Sassa T.
Gynecol Oncol. 2005 Dec;99(3):680-8. Epub 2005 Aug 19.
Cotylenin A, a differentiation-inducing agent, and IFN-alpha cooperatively induce apoptosis and have an antitumor effect on human non-small cell lung carcinoma cells in nude mice.
Honma Y, Ishii Y, Yamamoto-Yamaguchi Y, Sassa T, Asahi K.
Cancer Res. 2003 Jul 1;63(13):3659-66.
Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
Shankar S, Davis R, Singh KP, Kurzrock R, Ross DD, Srivastava RK.
Mol Cancer Ther. 2009 Jun;8(6):1596-605. Epub 2009 Jun 9.
Therapeutic strategy using phenotypic modulation of cancer cells by differentiation-inducing agents.
Honma Y, Akimoto M.
Cancer Sci. 2007 Nov;98(11):1643-51. Epub 2007 Jul 20. Review.
The rapamycin-regulated gene expression signature determines prognosis for breast cancer.
Akcakanat A, Zhang L, Tsavachidis S, Meric-Bernstam F.
Mol Cancer. 2009 Sep 24;8:75.
Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts.
Birle DC, Hedley DW.
Mol Cancer Ther. 2006 Oct;5(10):2494-502.
Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells.
Wang LH, Chan JL, Li W.
Int J Cancer. 2007 Jul 1;121(1):157-64.
Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells.
Dong K, Wang R, Wang X, Lin F, Shen JJ, Gao P, Zhang HZ.
Breast Cancer Res Treat. 2009 Feb;113(3):443-56. Epub 2008 Mar 10.
Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma.
Hui IC, Tung EK, Sze KM, Ching YP, Ng IO.
Liver Int. 2010 Jan;30(1):65-75. Epub 2009 Oct 20.
Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo.
Wärnberg F, White D, Anderson E, Knox F, Clarke RB, Morris J, Bundred NJ.
Breast Cancer Res. 2006;8(2):R21. Epub 2006 Apr 12.
Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells.
Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB, Meric-Bernstam F.
Clin Cancer Res. 2004 Oct 15;10(20):7031-42.
Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
Itashiki Y, Harada K, Ferdous T, Yoshida H.
Anticancer Res. 2007 Jul-Aug;27(4B):2365-75.
Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy.
Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M.
Transplantation. 2002 May 27;73(10):1565-72.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on